Nano-X Imaging Crescita futura
Criteri Future verificati 2/6
Si prevede che Nano-X Imaging aumenterà gli utili e i ricavi rispettivamente del 59.8% e 41.6% all'anno, mentre si prevede che l'EPS crescerà del 64.6% all'anno.
Informazioni chiave
59.8%
Tasso di crescita degli utili
64.63%
Tasso di crescita dell'EPS
| Healthcare crescita degli utili | 19.2% |
| Tasso di crescita dei ricavi | 41.6% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 07 Jul 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Jul 15
NNOX: Restructuring And Outsourced Production Will Drive Future Rebound Potential
Analysts have trimmed their price target on Nano-X Imaging by $2, reflecting updated assumptions for fair value at $7.4, a slightly higher discount rate of 8.58%, revised revenue growth expectations of 94.80%, a lower projected profit margin of 6.12%, and a higher future P/E of 122.52. What’s in the News for Nano-X Imaging Multiple law firms filed securities fraud class action lawsuits against Nano-X Imaging Ltd.
Aggiornamento narrativa • Jul 01
NNOX: Legal Overhang May Set Stage For Future Upside Repricing
Nano-X Imaging's analyst price target has been revised to $5.80 from $6.65. Analysts point to updated fair value estimates, a slightly higher discount rate, adjusted revenue growth assumptions, an updated profit margin outlook, and a lower future P/E multiple to support the change.Seeking Alpha • Jun 26
Nano-X Withdraws Guidance, Signals Rocky Road Ahead
Summary Nano-X Imaging Ltd. is downgraded to a sell as its narrative shifts from disruptive growth to execution and survival. NNOX's Q1 revenue rose 53% to $4.3M, but core Nanox.ARC hardware contributed minimally; most revenue stems from teleradiology and AI/Health IT. Withdrawn FY26 guidance, persistent cash burn, and explicit going concern warnings highlight severe liquidity and execution risks. Despite early commercial traction and partnerships, delayed deployments and a shrinking cash runway make near-term dilution highly likely. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 17
NNOX: New Distribution Agreements Will Support Future Stock Upside Potential
Analysts have reduced their Nano-X Imaging price target by $2 to reflect updated assumptions around long term revenue growth, profit margins, and future P/E multiples. What’s in the News for Nano-X Imaging Nano-X Imaging signed a U.S. distribution agreement through its subsidiary Nanox Impact Inc.Aggiornamento narrativa • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.Aggiornamento narrativa • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.Aggiornamento narrativa • Apr 12
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).Aggiornamento narrativa • Mar 28
NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.Aggiornamento narrativa • Mar 12
NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.Aggiornamento narrativa • Feb 25
NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).Aggiornamento narrativa • Feb 10
NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.Aggiornamento narrativa • Jan 27
NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).Aggiornamento narrativa • Jan 12
NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.Aggiornamento narrativa • Dec 26
NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.Aggiornamento narrativa • Dec 12
NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).Articolo di analisi • Oct 31
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento narrativa • Aug 15
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.Articolo di analisi • May 27
Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
One thing we could say about the analysts on Nano-X Imaging Ltd. ( NASDAQ:NNOX ) - they aren't optimistic, having just...
Nuova narrativa • Apr 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.Articolo di analisi • Apr 01
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 14
Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Summary Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system. Expect Nano-X to reach inflection point for revenue growth due to FDA approvals and the huge need for cost-effective X-ray monitoring and analyzing solutions. Read the full article on Seeking AlphaSeeking Alpha • Jan 04
Nano-X Imaging's Recent Surge Is Undeserved
Summary Nano-X Imaging shares surged 50.8% in a month, but I maintain a "sell' rating due to overvaluation and poor fundamentals. Despite some positive developments, Nano-X generates minimal revenue, significant net losses, and cash outflows, necessitating future capital raises. Recent FDA clearances and accolades are promising, but there's no concrete evidence that their technologies will achieve commercial success. The company's declining net cash balance and unjustified valuation reinforce my bearish stance on Nano-X Imaging. Read the full article on Seeking AlphaArticolo di analisi • Dec 05
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Key Insights Nano-X Imaging to hold its Annual General Meeting on 10th of December Total pay for CEO Erez Meltzer...Articolo di analisi • Nov 25
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Sep 29
Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Summary Nano-X Imaging has seen a significant decline in stock value, shedding over 37% since February, with no strong catalysts to reverse the trend. Nvidia’s small stake in Nano-X briefly boosted the stock, but without further investment or partnership, investor excitement has waned. Persistent financial losses, slow revenue growth, and limited global reach make Nano-X a high-risk investment with potential for further value erosion. Read the full article on Seeking AlphaArticolo di analisi • Apr 05
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 01
Nano-X Imaging: System Deployments Finally Begin
Summary Nano-X Imaging is executing its long-awaited roll-out strategy with multiple Nanox.ARC system deployments in the U.S. The company has also made progress in Africa and Latin America with installations and distribution agreements. However, financial performance is still lagging with scant details on how Nano-X will scale up to commercial scale. The story is improving, but there are still too many concerns for me to invest in NNOX stock. Read the full article on Seeking AlphaPrevisioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 87 | -18 | N/A | N/A | 2 |
| 12/31/2027 | 47 | -31 | N/A | N/A | 3 |
| 12/31/2026 | 26 | -45 | N/A | -31 | 3 |
| 3/31/2026 | 15 | -76 | -50 | -44 | N/A |
| 12/31/2025 | 13 | -75 | -45 | -41 | N/A |
| 9/30/2025 | 12 | -56 | -45 | -41 | N/A |
| 6/30/2025 | 12 | -56 | -42 | -38 | N/A |
| 3/31/2025 | 12 | -55 | -41 | -37 | N/A |
| 12/31/2024 | 11 | -54 | -39 | -37 | N/A |
| 9/30/2024 | 11 | -50 | -41 | -39 | N/A |
| 6/30/2024 | 10 | -57 | -44 | -42 | N/A |
| 3/31/2024 | 10 | -61 | -45 | -44 | N/A |
| 12/31/2023 | 10 | -61 | -48 | -45 | N/A |
| 9/30/2023 | 10 | -103 | -49 | -47 | N/A |
| 6/30/2023 | 10 | -101 | -45 | -42 | N/A |
| 3/31/2023 | 9 | -103 | -48 | -43 | N/A |
| 12/31/2022 | 9 | -113 | -51 | -43 | N/A |
| 9/30/2022 | 8 | -82 | -63 | -50 | N/A |
| 6/30/2022 | 5 | -77 | -65 | -49 | N/A |
| 3/31/2022 | 3 | -71 | -66 | -45 | N/A |
| 12/31/2021 | 1 | -62 | -61 | -38 | N/A |
| 9/30/2021 | N/A | -59 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -56 | N/A | N/A | N/A |
| 3/31/2021 | N/A | -49 | N/A | N/A | N/A |
| 12/31/2020 | N/A | -44 | -36 | -22 | N/A |
| 9/30/2020 | N/A | -44 | -13 | -12 | N/A |
| 6/30/2020 | N/A | -35 | -9 | -9 | N/A |
| 3/31/2020 | N/A | -29 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -23 | N/A | -6 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che NNOX rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che NNOX rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che NNOX rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di NNOX ( 41.6% all'anno) crescerà più rapidamente del mercato US ( 12.6% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di NNOX ( 41.6% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di NNOX è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/17 08:05 |
| Prezzo dell'azione a fine giornata | 2026/07/17 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Nano-X Imaging Ltd. è coperta da 8 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Scott Henry | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Ravi Misra | Berenberg |